NCT05617209View on ClinicalTrials.gov

In Vitro Correction of Thrombin Generation by Concizumab (Anti-TFPI) for Severe Hemophilia Patients

CompletedOBSERVATIONAL
Enrollment

20

Participants

Timeline

Start Date

September 7, 2021

Primary Completion Date

January 5, 2023

Study Completion Date

January 5, 2023

Conditions
Hemophilia
Interventions
OTHER

thrombin generation measurement

Thrombin generation will be measured in Platelets rich plasma induced either by 1 pM TF or 10 pM TF concentration in presence of different aTFPIAb concentrations (0; 0.5 µg/ml; 0.75 µg/ml; 1.0 µg/ml; 2.0 µg/ml; 4.0 µg/ml)

Trial Locations (1)

42055

CHU Saint-Etienne, Saint-Etienne

All Listed Sponsors
lead

Centre Hospitalier Universitaire de Saint Etienne

OTHER

NCT05617209 - In Vitro Correction of Thrombin Generation by Concizumab (Anti-TFPI) for Severe Hemophilia Patients | Biotech Hunter | Biotech Hunter